This is a Phase 2a safety and efficacy study of EVO101 Topical Cream, 0.1%, applied twice daily for 8 weeks in adults with mild-to moderate atopic dermatitis.
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis